newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

  • Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter.
  • EXXUA net revenue totaled $3.9 million in Q4 fiscal 2026 & $6.6 million for the full fiscal 2026 year following its commercial launch.
  • EXXUA fourth quarter fiscal 2026 prescriptions reached 3,323, a 138% increase from 1,398 in the third quarter.
  • ADHD Portfolio net revenue declined to $10.4 million in Q4 fiscal 2026 from $13.1 million in Q4 fiscal 2025 due to commercial prioritization of EXXUA & generic competition.
  • Pediatric Portfolio net revenue was $1.8 million in Q4 fiscal 2026 compared to $2.0 million in the prior-year quarter.
  • Full year fiscal 2026 net revenue decreased 13.3% to $57.6 million from $66.4 million in fiscal 2025.
  • Full year fiscal 2026 net loss was $14.3 million, including a $4.7 million derivative warrant liabilities loss, compared to a $13.6 million loss in fiscal 2025.
  • Fourth quarter fiscal 2026 Adjusted EBITDA was $0.5 million, down from $2.0 million in the prior-year quarter due to EXXUA commercialization investments.
  • Full year fiscal 2026 Adjusted EBITDA was a loss of $3.7 million compared to $9.2 million in fiscal 2025.
  • Cash balance was $26.3 million as of June 30, 2026, down from $31.0 million at June 30, 2025.
  • Aytu BioPharma hosted a conference call on September 22, 2026, at 4:30 p.m. Eastern time to discuss the results.
  • Management noted EXXUA adoption is broadening across prescribers & geographies with favorable early reimbursement dynamics.